Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Pancreatic Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Rituximab 226Cyclophosphamide 202fludarabine phosphate 108Peripheral Blood Stem Cell Transplantation 103Filgrastim 87Etoposide 76Cytarabine 70ibrutinib 68Mycophenolic Acid 67Bortezomib 66Whole-Body Irradiation 63Cyclosporine 63Melphalan 59Lenalidomide 59Bendamustine Hydrochloride 58Vincristine 53Radiotherapy 53fludarabine 52Tacrolimus 50Doxorubicin 48Busulfan 48Methotrexate 47Antilymphocyte Serum 42Prednisone 41Carmustine 40Dexamethasone 38Granulocyte Colony-Stimulating Factor 33venetoclax 32acalabrutinib 31zanubrutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × merestinib × Clear all
NCT02745769 2019-03-05

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Eli Lilly and Company

Phase 1 Completed
23 enrolled
GastrointestinalLymphoid

Colorectal Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡